CEBPA Gene Leukemia Acute Myeloid Somatic Genetic Test sale cost 4400 AED
APC Gene Desmoid Disease Hereditary Genetic Test sale cost 4400 AED APC Gene Desmoid Disease Hereditary Genetic Test Cost 5,600 د.إ Original price was: 5,600 د.إ.4,400 د.إCurrent price is: 4,400 د.إ.
MC1R Gene Melanoma Cutaneous Malignant Genetic Test sale cost 4400 AED MC1R Gene Melanoma Cutaneous Malignant Genetic Test Cost 5,600 د.إ Original price was: 5,600 د.إ.4,400 د.إCurrent price is: 4,400 د.إ.
Sale!

CEBPA Gene Leukemia Acute Myeloid Somatic Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The “CEBPA Gene Leukemia Acute Myeloid Somatic Genetic Test” is a specialized diagnostic procedure aimed at identifying mutations in the CEBPA gene, which are associated with acute myeloid leukemia (AML). This gene plays a crucial role in the development and function of white blood cells, and mutations can lead to uncontrolled cell growth, a hallmark of leukemia. The test is particularly significant for patients diagnosed with AML, as the presence of CEBPA mutations can influence treatment decisions and prognosis.

Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test involves analyzing the patient’s DNA to detect abnormalities in the CEBPA gene. It’s a sophisticated process that requires a sample of the patient’s blood or bone marrow. Given the complexity and the precision of the technology used, the cost of the test is 4400 AED. Identifying CEBPA mutations can help clinicians tailor treatment strategies more effectively, potentially improving patient outcomes. This test is an invaluable tool in the personalized medicine approach to treating acute myeloid leukemia.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

CEBPA Gene Leukemia Acute Myeloid Somatic Genetic Test

Welcome to DNA Labs UAE, a leading genetic lab offering the CEBPA Gene Leukemia Acute Myeloid Somatic Genetic Test. This test is designed to analyze the CEBPA gene, which is associated with acute myeloid leukemia (AML). AML is a type of cancer that affects the blood and bone marrow, causing abnormal production of white blood cells.

Test Details

The CEBPA gene is a gene that codes for a transcription factor involved in the development and differentiation of myeloid cells. Mutations in the CEBPA gene have been associated with AML. Our somatic NGS (Next-Generation Sequencing) genetic testing utilizes advanced technology to analyze the DNA sequence of cancer cells. This allows us to identify specific genetic mutations or alterations, such as those in the CEBPA gene, that may be driving the development or progression of AML.

Test Components

  • Test Name: CEBPA Gene Leukemia Acute Myeloid Somatic Genetic Test
  • Price: 4400.0 AED
  • Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
  • Report Delivery: 3 to 4 Weeks
  • Method: NGS Technology
  • Test Type: Cancer
  • Doctor: Oncologist
  • Test Department: Genetics

Pre Test Information

Before undergoing the CEBPA Gene Leukemia Acute Myeloid Somatic Genetic Test, it is important to provide the clinical history of the patient who is going for the test. Additionally, a genetic counseling session will be conducted to draw a pedigree chart of family members affected with CEBPA Gene Leukemia. This information helps us better understand the genetic makeup and potential risk factors associated with the disease.

Benefits of CEBPA Gene Leukemia Acute Myeloid Somatic Genetic Test

The somatic NGS genetic testing for the CEBPA gene in AML provides valuable information for personalized treatment approaches and improved patient outcomes. By identifying mutations in the CEBPA gene, healthcare professionals can better understand the underlying genetic changes driving the development of AML. This information can be used to guide treatment decisions, as certain mutations may be associated with different prognoses or response to specific therapies. Additionally, somatic NGS testing can help identify potential targeted therapies that may specifically target the mutated CEBPA gene or its downstream effects.

At DNA Labs UAE, we are committed to providing accurate and reliable genetic testing services. Our team of experienced professionals, including oncologists and geneticists, ensures that each test is conducted with utmost precision and care. To learn more about the CEBPA Gene Leukemia Acute Myeloid Somatic Genetic Test or to schedule an appointment, please contact us.

Test Name CEBPA Gene Leukemia acute myeloid somatic Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Cancer
Doctor Oncologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for CEBPA Gene Leukemia, acute myeloid, somatic NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with CEBPA Gene Leukemia, acute myeloid, somatic NGS Genetic DNA Test gene CEBPA
Test Details

The CEBPA gene is a gene that codes for a transcription factor involved in the development and differentiation of myeloid cells. Mutations in the CEBPA gene have been associated with acute myeloid leukemia (AML).

Leukemia is a type of cancer that affects the blood and bone marrow, causing abnormal production of white blood cells. AML is a specific subtype of leukemia characterized by the rapid growth of abnormal myeloid cells in the bone marrow.

Somatic NGS (Next-Generation Sequencing) genetic testing is a technique used to analyze the DNA sequence of cancer cells. It allows for the identification of specific genetic mutations or alterations that may be driving the development or progression of cancer. In the case of AML, somatic NGS genetic testing can be used to detect mutations in genes such as CEBPA that are associated with the disease.

By identifying mutations in the CEBPA gene through somatic NGS genetic testing, healthcare professionals can better understand the underlying genetic changes driving the development of AML. This information can be used to guide treatment decisions, as certain mutations may be associated with different prognoses or response to specific therapies. Additionally, somatic NGS testing can help identify potential targeted therapies that may specifically target the mutated CEBPA gene or its downstream effects.

Overall, somatic NGS genetic testing for the CEBPA gene in AML can provide valuable information for personalized treatment approaches and improved patient outcomes.

SKU: TEST-4509 Category:

Related products